Anbogen Therapeutics, Inc.

NT$9.58As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7784—

Country Taiwan

PE (Fwd) •••

TSR 10Y CAGR —

Div yield —

ROE —

—

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap —

ROIC —

SE Grade™

Value

Quality

Moat

Consensus

Reference

NT$11

18.42%

1037.67%

Hold 12|3|1|10|7

TTM

FYE 31 Dec TWD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

8.334

RevenueNT$B

17.97

18.11

18.17

18.09

17.94

17.85

17.47

17.36

17.37

17.72

8.508

(0.24%)

(0.29%)

16.89

Revenue growth%

31.87

33.83

32.61

29.94

29.34

28.63

31.32

32.85

32.48

26.19

31.32

31.87

17.67

Gross margin%

18.69

17.64

20.43

20.19

17.86

17.45

14.93

17.04

18.44

16.12

12.48

17.04

17.75

23.44

Operating margin%

17.73

14.78

12.24

12.61

15.17

17.45

19.27

17.06

16.55

14.50

29.66

17.06

15.86

16.75

Net margin%

17.67

17.38

19.38

22.17

24.73

25.27

23.91

25.54

26.04

24.72

20.17

25.27

24.32

6.112

P/E ratio (avg)x

23.15

25.17

24.96

27.74

26.84

26.07

30.35

29.98

35.43

39.12

7.097

30.35

27.29

13.08

EV/EBITx

23.72

23.71

25.21

22.64

24.90

27.91

26.12

25.11

23.16

22.80

21.41

25.11

24.31

24.10

FCF yield (avg)%

6.84

4.54

6.72

7.44

9.59

7.47

6.44

9.28

12.07

9.43

6.04

9.28

7.46

28.78

FCF margin%

2.83

4.31

3.83

6.57

3.98

3.75

4.09

2.17

0.40

14.06

2.17

3.79

1.290

FCF / Net incomex

0.343

0.376

0.415

0.454

0.536

0.556

0.637

0.756

0.851

0.848

0.385

0.756

0.546

28.23

ROIC%

14.46

14.31

15.77

18.36

19.84

20.43

22.09

21.37

20.27

19.72

20.88

20.43

19.78

22.33

Return on equity%

5.78

6.47

8.05

9.78

11.15

9.25

8.57

7.10

9.80

8.69

2.00

8.69

8.63

20.86

Return on assets%

29.99

31.93

32.30

29.67

29.61

26.99

26.03

26.87

28.85

31.63

26.80

26.99

29.64

0.71

EPSNT$

1.12

1.14

1.08

1.15

1.17

1.16

1.03

0.95

0.97

1.05

0.73

(2.11%)

(0.61%)

—

16.06

EPS growth%

28.78

27.00

27.16

27.04

26.37

28.38

28.30

25.44

26.28

24.85

14.52

26.28

27.02

0.66

Bookvalue per shNT$

0.59

0.52

0.48

0.43

0.40

0.38

0.42

0.38

0.40

0.52

(1.22%)

(5.10%)

—

1.51

FCF per shareNT$

0.31

0.35

0.40

0.46

0.54

0.62

0.65

0.68

0.79

0.74

1.27

6.74%

9.38%

—

0.27

Dividend per shNT$

0.37

0.40

0.37

0.39

0.37

0.38

0.34

0.32

0.31

0.29

0.62

(4.63%)

(2.81%)

—

18.20

Div yield (avg)%

9.55

10.87

10.52

13.28

14.29

16.41

13.41

12.57

11.42

8.53

16.64

12.57

11.99

10.30

Payout ratio%

23.95

21.24

19.01

21.62

23.98

21.26

21.85

24.32

27.05

24.23

21.38

24.23

22.90

325.5

Shares (diluted)M

324.3

307.2

320.9

317.7

294.8

302.7

284.9

275.3

273.7

258.0

324.9

(2.63%)

(2.36%)

19.40

Buyback yield%

17.51

16.04

14.72

14.27

13.80

15.41

17.75

14.78

12.05

13.64

25.37

14.78

14.75

1.301

D/E ratiox

1.428

1.635

1.850

1.904

2.021

2.238

2.486

2.631

2.636

3.059

0.195

2.631

2.130

15.83

Enterprise valueNT$B

12.80

12.16

12.31

12.22

12.83

12.47

10.83

10.51

10.81

11.12

12.05

(2.82%)

(0.66%)

15.57

LT debtNT$B

11.96

13.78

15.91

16.42

18.72

18.41

17.17

19.45

19.54

18.49

16.33

(0.25%)

5.67%

Peers (US$46.46M)

Cap (US$)

Timing Pharmaceutial…

51.10M

—

Gin Hwa Biotech…

48.71M

25.21x

Anya Biopharm Inc.

38.85M

—

Optipharm.CO.,LTD

46.94M

—

Capital

TTM

10Y

Leveragex

0.512

(0.431)

(0.296)

EBIT/Intx

0.351

0.243

0.269

Own earn%

(82.93)

3.33

4.92

Sh yield%

37.59

27.35

27.20

Owners

Insiders/Inst%

0.63

66.91

Short interest%

2.20

SBC / revenue%

0.74

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

12–19

$1 testx

0.6

Incr. ROIC%

Anbogen Therapeutics, Inc. develops precision anti-cancer drugs and conducts research and development in oncology. The company develops precision oncology drugs, including clinical-stage assets such as ABT-101 for non-small cell lung cancer with HER2 exon20 insertion mutations and ABT-301 for metastatic colorectal cancer in combination with anti-PD-1 therapies.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

NT$17.72B

(0.29%)

1.00×

Cost of revenue

NT$11.63B

(0.28%)

1.00×

Operating expenses

NT$2.367B

(0.40%)

0.99×